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menAbstract Rheumatoid arthritis (RA) can inﬂuence sexual function due to several reasons, such as
pain, restricted joint movements, fatigue, and problems with self-esteem and body image. It can
affect serum androgen levels, which may be another cause of sexual dysfunction.
Aim of the work: To compare between serum androgen levels in male patients with RA and nor-
mal males, and between the presence of erectile dysfunctions (EDs) in both groups.
Patients and methods: This study was performed on 42 individuals; 24 male patients suffering
from RA and 18 healthy control male subjects. Patients were subjected to full history taking, full
locomotor examination, and calculation of disease activity score, using 28 joint count (DAS-28).
Assessment of serum dehydro-epiandrosterone sulfate (DHEA), total and free testosterone was done
for all subjects. All subjects were asked to complete the Sexual Health Inventory for Men (SHIM).
Results: There were highly statistically signiﬁcant differences in the levels of serum DHEA, total
and free testosterone levels between patients and controls (P< 0.001). Occurrence of EDs was more
frequent in RA patients (45.8%) than in the control subjects (11.1%) and comparison between
SHIM score of both groups revealed highly statistically signiﬁcant differences (P< 0.001) with
higher mean values in the control group.
Conclusion: Erectile dysfunction is a prominent problem in male patients with RA. Assessment of
sexual functions of RA males should be a part of routine assessment of disease status. Andrological
consultation is recommended for a proper management of the condition.
 2013 Production and hosting by Elsevier B.V. on behalf of Egyptian Society for Joint Diseases and
Arthritis. Open access under CC BY-NC-ND license.1. Introduction
Clinical and epidemiological evidence supports that androgens
protect males more than females from the development of im-
mune-inﬂammatory diseases [1]. In patients with rheumatoid
arthritis (RA), there have been reports of normal, increased,
and decreased dehydro-epiandrosterone sulfate (DHEAS)
values [2].
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correlated with RA disease activity and DHEAS levels are in-
versely correlated with both disease duration and clinical
severity [3]. Male gender has been found to be a major predic-
tor of remission in early RA [4].
It was hypothesized that low total and free testosterone levels
and low DHEAS levels measured before the onset of disease
would be associated with an increased risk of RA in women [5].
Rheumatoid arthritis can inﬂuence sexual function due to
several reasons. People with RA suffer from pain, restricted
joint movements, and fatigue, and they can have problems
with self-esteem and body image. It is also possible that med-
ications can cause sexual problems. Research on the subject is
limited and shows a divergent picture [6].
It has been suggested that questions about sexuality asked
via a self questionnaire or during a face-to-face interview
may deserve to be among the domains used to monitor the
course of the disease, as well as functional capabilities, quality
of life and fatigue [7].
The aim of this work is to compare between serum andro-
gen levels in RA male patients and normal males, and to com-
pare between the presence of erectile dysfunctions (EDs)
between male patients with RA and normal males.
2. Patients and methods
2.1. Patients
This study was performed on 42 males, recruited from the out-
patient clinics, in-patient departments and follow up units of
Rheumatology and Rehabilitation & Dermatology, Venereol-
ogy and Andrology Depatments, Faculty of Medicine, Zagazig
University. Twenty-four of them diagnosed as RA according
to the revised American College of Rheumatology (ACR) cri-
teria for classiﬁcation of RA [8] (group I) and 18 healthy vol-
unteers (group II), age matched with patients, were taken as
control.
All of the patients were receiving either hydroxychloro-
quine, sulfasalazine, methotrexate, leﬂunomide or combina-
tions of them.
We selected RA patients who were not on corticosteroid
therapy for the last 6 months. Patients with endocrinal disor-
ders, those who have taken anabolic steroids at anytime in
their lives and patients with erectile dysfunctions prior to the
onset of RA were excluded from this study.
The study was approved by the Local Ethics Committee of
the university. An informed consent was obtained from each
participant.
2.2. Clinical and laboratory evaluation
Patients were subjected to full history taking and a thorough
clinical examination of the locomotor system. Disease activity
was assessed by disease activity score, using 28 joint count
(DAS-28) [9].
They were, also, subjected to andrological history taking,
including body conﬁguration, degree of virilization and puber-
tal history. Andrological examination included assessment of
testicular volume & consistency, inguinal and penile examina-
tion, epididymal and scrotal examination and examination of
gynaecomastia.Laboratory investigations included erythrocyte sedimenta-
tion rate (ESR), C-reactive protein (CRP), rheumatoid factor
(RF) titer, dehydro-epiandrosterone sulfate (DHEA), total
and free testosterone levels.
Our laboratory reference range for serum DHEA is 80–
560 ug/dl, for free testosterone is 50–300 pg/ml and for total
testosterone is 2.8–8 ng/ml.
2.3. Assessment of male sexual functions
All subjects involved in the study were asked to complete the
Sexual Health Inventory for Men (SHIM) [10], to assess their
sexual functions.
The subject is asked to complete a questionnaire of ﬁve
items to identify the presence or absence of ED. Each item
has a score from 0 to 5. These items focused on erectile func-
tion and intercourse satisfaction. ED is classiﬁed into ﬁve
severity levels: Scoring more than 21 is considered normal,
17–21 mild ED, 12–16 mild to moderate ED, 8–11 moderate
ED, 1–7 severe ED.
Statistical analysis: Data were analyzed using SPSS soft-
ware package version 18.0 (SPSS, Chicago, IL, USA). Quanti-
tative data were expressed using range, mean and standard
deviation, while qualitative data were expressed in frequency
and percent. Quantitative data were analyzed using Mann–
Whitney test to compare between the two groups. Fisher exact
test was used when the number of cases is less than ﬁve. Pear-
son coefﬁcient was used to analyze the correlation between any
two quantitative variables. P value was assumed to be signiﬁ-
cant at 0.05 or less.3. Results
3.1. Demographic data of subjects involved in the study
This study included 24 male patients suffering from adult onset
RA, theirdiseasedurationranged from1to13 years,withamean
of 4.28 ± 3.13. Their ages ranged from 24 to 40 years, with a
mean of 31.33 ± 7.35. Eighteen healthy male subjects were
taken as control group. Their ages ranged from 25 to 40 years,
with a mean of 30.87 ± 7.44. All of patients and subjects were
married.
3.2. Serum levels of male sex hormones and SHIM scores in the
two studied groups
Comparison between the two groups as regards their serum
DHEA, total and free testosterone levels revealed highly statis-
tically signiﬁcant differences, with much higher mean values in
the control group (Table 1).
There were not any statistically signiﬁcant correlations be-
tween serum levels of these hormones and patients’ ages, dis-
ease durations, ESR, CRP, RF titer or DAS-28. (See Tables
2 and 3).
3.3. Frequency of erectile dysfunctions in the two studied groups
Comparison between both groups as regards the occurrence of
ED revealed a statistically signiﬁcant difference (P< 0.05). In
Table 2 Grading of erectile dysfunctions in males of both
groups.
RA (total No. = 24) Control (total No. = 18)
Normal
No. 13 16
% 54.2 88.9
Mild
No. 2 2
% 8.3 11.1
Mild to moderate
No. 2 0
% 8.3
Moderate
No. 5 0
% 20.8
Severe
No. 2 0
% 8.3
Normal: >21.
Mild: 17–21.
Mild to moderate: 12–16.
Moderate: 8–11.
Severe: 1–7.
Table 1 Difference between males of RA group & control
male subjects as regards their sex hormone levels and SHIM
score.
RA Control t P
SHIM score
Range 6–24 19–25 65.54 0.000**
Mean ± SD 17.5 ± 6.8 23.11 ± 1.6
DHEA (ug/dl)
Range 32–111 93–426 48.45 0.000**
Mean ± SD 71.13 ± 22.71 236.61 ± 105.41
Total testosterone (ng/ml)
Range 0.3–2.8 2.7–7.9 27.93 0.000**
Mean ± SD 1.5 ± 0.69 4.72 ± 1.75
Free testosterone (pg/ml)
Range 11–52 66–281 31.86 0.000**
Mean ± SD 32.75 + 14.26 188.06 + 70.56
** Signiﬁcance at P < 0.001.
Table 3 Correlations between SHIM score and parameters of
disease activity & androgen levels in patients with RA.
SHIM
R P
ESR (mm/h) 0.09 0.66
CRP (mg/dl) 0.19 0.37
DAS 28 0.21 0.32
DHEA (ug/dl) 0.33 0.03*
Total testosterone (ng/ml) 0.48 0.001**
Free testosterone (pg/ml) 0.53 0.000**
SHIM: Sexual health inventory for men.
ESR: Erythrocyte sedimentation rate.
CRP: C-reactive protein.
DAS 28: Disease activity score using 28 joint count.
DHEA: Dehydro-epiandrosterone sulfate.
** Signiﬁcance at P < 0.001.
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(54.2%) patients had normal scores. In the control group, only
2 (11.1%) subjects suffered from ED and 16 (88.9%) subjects
had normal scores. In RA group, there were 5 (20.8%) patients
suffered from moderate ED. While none of the control subjects
had suffered from moderate ED.
3.4. Correlations between SHIM score and both parameters
of disease activity and sex hormone levels in RA group
In this study, we found no signiﬁcant correlation between the
SHIM score and ESR, CRP or DAS-28 in RA patients. On thecontrary, there were highly statistically signiﬁcant correlations
between total and free testosterone levels and the SHIM score
(P< 0.001), and the correlation was signiﬁcant concerning the
DHEA level (P< 0.05).
4. Discussion
Rheumatoid arthritis (RA) is a chronic inﬂammatory joint dis-
ease that is characterized by daily pain, stiffness and fatigue
which, in turn, limits activities of daily living [11].There is very
little evidence that the rheumatoid process itself may inﬂuence
the ability to have sexual intercourse [12].
In this work, we evaluated the levels of DHEA, total and
free testosterone in RA male patients and control subjects. Be-
sides, we compared between sexual function, in both groups,
by asking patients and subjects to complete the SHIM.
In this study, there were much lower levels of male sex hor-
mones in RA patients than in control subjects.
Old reports stated that blood levels of DHEAS were lower
in patients with RA, and these levels were further reduced in
patients receiving steroids or in those with a history of steroid
use [13]. A more recent study found that the levels of DHEAS
and ACTH were decreased in RA patients receiving steroid
therapy [14]. DHEAS, total and free testosterone were signiﬁ-
cantly decreased in patients with RA compared to control
subjects [15].
We suppose that low levels of serum androgens in this study
were due to the disease process itself, as all of our patients did
not receive any steroid treatment during the previous
6 months. It has been stated that during a chronic inﬂamma-
tory process like active RA, levels of both serum testosterone
and, in particular, serum DHEAS become lower [16]. There
are old lines of evidence of downregulation of ACTH and cor-
tisol secretion in RA patients [17]. Others found that in early
RA, current inﬂammation seemed to affect the hypophyseal
gonadal axis (HPG axis), mainly at the gonadal rather than
the hypothalamic–pituitary level [18]. It has been reported that
the observed androgen deﬁciency reported in existing RA is
most probably a consequence of the disease, and not causal
[5]. So, low serum androgen levels in RA patients are caused
by affection of both adrenal and gonadal secretions of
testosterone.
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were not correlated neither with parameters of disease activity
(ESR or CRP) nor with DAS-28 or RF titer, disease duration
or patients’ ages.
Yukioka and colleagues found that DHEAS was negatively
correlated with age but not with ESR or CRP [14]. More re-
cent studies stated that serum testosterone and DHEAS levels
are inversely correlated with RA activity. Besides, negative
correlation was found between testosterone, and DHEAS lev-
els and parameters of inﬂammation, such as TNF-a [15].
Cutolo found that serum testosterone levels were inversely cor-
related with RA activity and DHEAS levels were inversely cor-
related with both disease duration and clinical severity in RA
patients [19].
In this work, patients’ ages ranged from 24 to 40 years,
which is younger than the age in which serum androgens are
expected to be lowered as a result of the normal aging process.
Besides, the RA disease duration ranged from 1 to 13 years,
meaning that the chronicity of disease is not claimed to be
the cause of low serum androgen levels, and that hypoandrog-
enicity is due to the disease process itself, whether early onset
or not.
There is increasing awareness that clinical and laboratory
markers do not capture the full experience of disability result-
ing from joint inﬂammation and deformities with RA [11].
Comparison between sexual functions in both groups, using
SHIM score, revealed high statistically signiﬁcant difference,
with much lower mean value in RA males.
In RA patients, 45.8% suffered from ED of different grades
while only 11.1% of control subjects suffered from ED of mild
grade only. SHIM scores in RA patients were not correlated
with parameters of disease activity, but were highly statistically
signiﬁcant correlated with sex hormone levels.
Our results in this point are similar to those of a recent
Egyptian study which reported that sexual dysfunction, in
the form of ED, was present in 53.8% of RA male patients
[20].
The identiﬁcation of factors involved in the sexual prob-
lems of RA patients is challenging, given the large number
of factors involved and possible need for interpretation [12].
In an old study, factors signiﬁcantly associated with sexual dif-
ﬁculties included tender joint count, pain, and functional dis-
ability. In addition, hip joint involvement was signiﬁcantly
associated with sexual problems [21].
Regarding females, El Miedany and colleagues found that
problems with orgasm, lubrication and sexual satisfaction were
the most prevalent problems in women with RA [20]. Recently,
RA is observed to have negative effects on sexual functions of
women. Presence of depressive symptoms with RA and in-
creased disease severity increase the degree of sexual dysfunc-
tion [22].
Moreover, social isolation and loss of self esteem [23] and
loss of intimate relationships [24] in RA preclude male and fe-
male patients from living a fulﬁlled life.
The vascular causes of EDs should not be neglected. Sheane
and colleagues found that erectile dysfunction was more com-
mon in patients with RA compared with other forms of arthri-
tis, particularly in those with known cardiovascular diseases
(CVD). They recommended including standard ED scoring
in the holistic assessment of RA which may be valuable in
the early detection of sub-clinical vascular disease in these
patients [25].Recently, endothelial dysfunction has been claimed to be
the cause of association between ED and RA. It was recom-
mended that physicians treating RA should be sensitive to
any complaints concerning sexual function [26].
From the previous discussion, we conclude that erectile dys-
function is a prominent problem in male patients with RA.
This study focused on the association of these erectile dysfunc-
tions with serum androgen levels, but the vascular factor
should be kept in mind. More detailed investigations are re-
quired to differentiate between hypoandrogenicity of adrenal
or testicular origin. Risk factors of atherosclerosis should be
investigated as well.
We recommend assessment of sexual functions of RA males
as a part of their routine assessment of disease status. Andro-
logical consultation is recommended for proper management
of the condition in order to improve an important aspect of pa-
tients’ lives.Conﬂict of interest
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